Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness

Int J Mol Sci. 2014 Jul 30;15(8):13299-316. doi: 10.3390/ijms150813299.


It has been suggested that urinary PCA3 and TMPRSS2:ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2:ERG (T2) scores were assessed in 154 patients who underwent radical prostatectomy for biopsy-proven prostate cancer. Univariate and multivariate analyses using logistic regression and decision curve analyses were performed. All three markers were predictors of a tumor volume≥0.5 mL. Only PHI predicted Gleason score≥7. T2 score and PHI were both independent predictors of extracapsular extension(≥pT3), while multifocality was only predicted by PCA3 score. Moreover, when compared to a base model (age, digital rectal examination, serum PSA, and Gleason sum at biopsy), the addition of both PCA3 score and PHI to the base model induced a significant increase (+12%) when predicting tumor volume>0.5 mL. PHI and urinary PCA3 and T2 scores can be considered as complementary predictors of cancer aggressiveness at prostatectomy.

Publication types

  • Evaluation Study

MeSH terms

  • Aged
  • Antigens, Neoplasm / urine*
  • Area Under Curve
  • Biomarkers / urine
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Peptide PHI / blood*
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery
  • ROC Curve
  • Serine Endopeptidases / urine*


  • Antigens, Neoplasm
  • Biomarkers
  • Peptide PHI
  • prostate cancer antigen 3, human
  • Serine Endopeptidases
  • TMPRSS2 protein, human
  • Prostate-Specific Antigen